Teruhiko Mizumoto
Kumamoto, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
SUrvey of renal Biopsy registry database and Anticancer dRUg therapy in Japan (SUBARU-J study).
Journal: Clinical kidney journal
Published: July 30, 2024
Alvespimycin is identified as a novel therapeutic agent for diabetic kidney disease by chemical screening targeting extracellular vesicles.
Journal: Scientific reports
Published: March 04, 2024
A case of chyluria with nephrotic-range proteinuria caused by lymphatic malformation, leading to a diagnosis of Klippel-Trenaunay syndrome.
Journal: CEN case reports
Published: August 09, 2022
A novel VCP modulator KUS121 exerts renoprotective effects in ischemia-reperfusion injury with retaining ATP and restoring ERAD-processing capacity.
Journal: American journal of physiology. Renal physiology
Published: March 28, 2022
A novel technique for assessment of post-extubation airway obstruction can successfully replace the conventional cuff leak test: a pilot study.
Journal: BMC anesthesiology
Published: October 19, 2021
A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte injury in metabolic syndrome model rats.
Journal: Journal of pharmacological sciences
Published: March 16, 2021
Circulating angiopoietin-like protein 2 levels and mortality risk in patients receiving maintenance hemodialysis: a prospective cohort study.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: May 29, 2019
Doxycycline attenuates cisplatin-induced acute kidney injury through pleiotropic effects.
Journal: American journal of physiology. Renal physiology
Published: July 26, 2018
A serine protease inhibitor attenuates aldosterone-induced kidney injuries via the suppression of plasmin activity.
Journal: Journal of pharmacological sciences
Published: March 13, 2016
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Journal: Journal of pharmacological sciences
Published: August 25, 2015
The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects.
Journal: Nephron
Published: May 02, 2014
Last Updated: 09/26/2026